by The myocardial infarction market involves products that are used in the treatment of heart attack or myocardial infarction. Myocardial infarction, commonly known as a heart attack, occurs due to the rupture of atherosclerotic plaques in the coronary arteries causing a blockage restricting blood supply to the heart. The key symptoms include severe chest pain radiating to the left arm, shortness of breath, nausea, and cold sweat. Treatment mainly involves restoring blood flow to the heart, reducing further damage, and preventing complications and recurrence through medications. Some of the mainstay treatment in myocardial infarction includes antithrombotic agents, vasodilators, beta blockers, and statins.
The global myocardial infarction market is estimated to be valued at US$ 2037.51 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of cardiovascular diseases such as coronary artery disease, peripheral artery disease, heart failure, stroke and congenital heart disease is the primary driver boosting demand for myocardial infarction treatment market worldwide. As per the statistics by World Health Organization, cardiovascular diseases are the leading global cause of death, accounting for over 17.9 million deaths annually. Heart attack is one of the major cardiovascular events caused mainly due to atherosclerosis leading to myocardial infarction. The growing geriatric population and rising lifestyle diseases such as diabetes, obesity and high blood pressure further increase the risk of heart attacks thereby propelling the myocardial infarction market growth over the forecast period. Rapid advances in the development of novel antithrombotic and vasodilator drugs with improved safety and efficacy aimed at restoring normal blood flow and preventing future complications will also contribute to the market expansion. However, high cost of treatment and side effects associated with some drugs may restrain the market growth to some extent.
SWOT Analysis
Strength: Advanced diagnostics and treatments are improving outcomes for myocardial infarction patients. Devices like stents and other devices are improving treatment options.
Weakness: High cost of treatment poses an economic burden. Lifestyle diseases leading to risk factors are on the rise.
Opportunity: Growth in elderly population prone to cardiac issues increases market opportunity. Emerging markets offer growth potential.
Threats: Product recalls and safety issues can impact brand image of companies. Generics enter market after patent expiries increase competition.
Key Takeaways
The Global Myocardial Infarction Market Size is expected to witness high growth. Advancements in technologies for diagnostics and interventional procedures are helping improve patient outcomes.
North America currently dominates the myocardial infarction market owing to presence of major players, high healthcare spending and large patient population diagnosed with cardiovascular diseases annually. However, Asia Pacific is expected to grow at fastest CAGR during the forecast period due to rising geriatric population, growing incidence of lifestyle diseases and increasing healthcare spending in the region.
Key players operating in the myocardial infarction market are Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA. These players are focusing on collaborations and new product launches to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
